Arvinas Inc (ARVN)
24.80
-1.18
(-4.54%)
USD |
NASDAQ |
Jul 02, 16:00
24.65
-0.15
(-0.60%)
After-Hours: 20:00
Arvinas Research and Development Expense (TTM): 368.80M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 368.80M |
| December 31, 2023 | 379.80M |
| September 30, 2023 | 382.90M |
| June 30, 2023 | 374.50M |
| March 31, 2023 | 346.40M |
| December 31, 2022 | 315.10M |
| September 30, 2022 | 278.70M |
| June 30, 2022 | 241.80M |
| March 31, 2022 | 209.50M |
| December 31, 2021 | 180.40M |
| September 30, 2021 | 151.74M |
| June 30, 2021 | 141.16M |
| Date | Value |
|---|---|
| March 31, 2021 | 121.57M |
| December 31, 2020 | 108.40M |
| September 30, 2020 | 95.58M |
| June 30, 2020 | 82.15M |
| March 31, 2020 | 74.74M |
| December 31, 2019 | 67.20M |
| September 30, 2019 | 61.34M |
| June 30, 2019 | 57.90M |
| March 31, 2019 | 52.24M |
| December 31, 2018 | 45.19M |
| September 30, 2018 | 37.32M |
| June 30, 2018 | 31.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
61.34M
Minimum
Sep 2019
382.90M
Maximum
Sep 2023
209.57M
Average
180.40M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc | 10.67B |
| BridgeBio Pharma Inc | 503.82M |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Agios Pharmaceuticals Inc | 296.84M |
| Krystal Biotech Inc | 45.10M |